Aarti Drugs Q3: PAT Surges 58%, But EBITDA Dips Amid Margin Squeeze

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Aarti Drugs Q3: PAT Surges 58%, But EBITDA Dips Amid Margin Squeeze
Overview

Aarti Drugs posted an 8% YoY revenue increase to ₹602.9 crore for Q3 FY26, with PAT soaring 58% YoY to ₹40.5 crore. However, EBITDA declined 10% YoY to ₹56.3 crore, and margins contracted due to transient market dynamics and new facility costs. Growth in Formulations and Specialty Chemicals offset API segment flatness.

📉 The Financial Deep Dive

The Numbers:
Aarti Drugs Limited reported a consolidated revenue of ₹602.9 crore for the third quarter of FY26, marking an 8% increase year-on-year (YoY) from ₹557.1 crore in Q3 FY25. Quarter-on-quarter (QoQ), revenue saw an 8% decrease. EBITDA declined by 10% YoY to ₹56.3 crore, with a significant 33% QoQ drop. Earnings Per Share (EPS) for Q3 FY26 stood at ₹4.44, up from ₹4.22 in the prior year period.

The Quality:
While Profit After Tax (PAT) demonstrated a robust 58% YoY growth to ₹40.5 crore, this was achieved alongside a contraction in profitability at the operating level. The EBITDA margin deteriorated by 190 basis points (bps) YoY to 9.3%, down from 11.2% in Q3 FY25. Sequentially, margins experienced a sharper 360 bps decline. The PAT margin, however, improved to 6.7% from 4.6% YoY, indicating potential benefits from lower finance costs or tax rates, or a favorable product mix contributing to higher net profit despite operating margin pressure.

The Grill:
Mr. Adhish Patil, CFO & COO, attributed the Q3 EBITDA contraction to "transient market dynamics and initial absorption of commissioning costs for new facilities." He noted that January sales showed encouraging momentum and a positive trend for upcoming quarters. The company highlighted the successful operationalization of its backward integration plant in Sayakha for methyl amines and the scaling of its Salicylic Acid plant in Tarapur, with downstream implementation underway. Management views the company as being at an "inflection point" driven by stable prices and picking volume momentum, with a focus on operational efficiency, margin improvement, and capacity ramp-up.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.